| Product Code: ETC10689381 | Publication Date: Apr 2025 | Updated Date: Sep 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Bhawna Singh | No. of Pages: 65 | No. of Figures: 34 | No. of Tables: 19 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Greece Oncology Companion Diagnostics Market Overview |
3.1 Greece Country Macro Economic Indicators |
3.2 Greece Oncology Companion Diagnostics Market Revenues & Volume, 2021 & 2031F |
3.3 Greece Oncology Companion Diagnostics Market - Industry Life Cycle |
3.4 Greece Oncology Companion Diagnostics Market - Porter's Five Forces |
3.5 Greece Oncology Companion Diagnostics Market Revenues & Volume Share, By Technology, 2021 & 2031F |
3.6 Greece Oncology Companion Diagnostics Market Revenues & Volume Share, By Indication, 2021 & 2031F |
3.7 Greece Oncology Companion Diagnostics Market Revenues & Volume Share, By End User, 2021 & 2031F |
3.8 Greece Oncology Companion Diagnostics Market Revenues & Volume Share, By Sample Type, 2021 & 2031F |
4 Greece Oncology Companion Diagnostics Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of cancer in Greece |
4.2.2 Growing adoption of precision medicine in oncology |
4.2.3 Rising demand for personalized treatment options |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements for companion diagnostics |
4.3.2 Limited reimbursement policies for companion diagnostics |
4.3.3 High cost associated with companion diagnostic tests |
5 Greece Oncology Companion Diagnostics Market Trends |
6 Greece Oncology Companion Diagnostics Market, By Types |
6.1 Greece Oncology Companion Diagnostics Market, By Technology |
6.1.1 Overview and Analysis |
6.1.2 Greece Oncology Companion Diagnostics Market Revenues & Volume, By Technology, 2021 - 2031F |
6.1.3 Greece Oncology Companion Diagnostics Market Revenues & Volume, By PCR-Based, 2021 - 2031F |
6.1.4 Greece Oncology Companion Diagnostics Market Revenues & Volume, By NGS-Based, 2021 - 2031F |
6.1.5 Greece Oncology Companion Diagnostics Market Revenues & Volume, By IHC-Based, 2021 - 2031F |
6.1.6 Greece Oncology Companion Diagnostics Market Revenues & Volume, By FISH-Based, 2021 - 2031F |
6.2 Greece Oncology Companion Diagnostics Market, By Indication |
6.2.1 Overview and Analysis |
6.2.2 Greece Oncology Companion Diagnostics Market Revenues & Volume, By Lung Cancer, 2021 - 2031F |
6.2.3 Greece Oncology Companion Diagnostics Market Revenues & Volume, By Breast Cancer, 2021 - 2031F |
6.2.4 Greece Oncology Companion Diagnostics Market Revenues & Volume, By Colorectal Cancer, 2021 - 2031F |
6.2.5 Greece Oncology Companion Diagnostics Market Revenues & Volume, By Ovarian Cancer, 2021 - 2031F |
6.3 Greece Oncology Companion Diagnostics Market, By End User |
6.3.1 Overview and Analysis |
6.3.2 Greece Oncology Companion Diagnostics Market Revenues & Volume, By Hospitals, 2021 - 2031F |
6.3.3 Greece Oncology Companion Diagnostics Market Revenues & Volume, By Research Centers, 2021 - 2031F |
6.3.4 Greece Oncology Companion Diagnostics Market Revenues & Volume, By Diagnostic Labs, 2021 - 2031F |
6.3.5 Greece Oncology Companion Diagnostics Market Revenues & Volume, By Pharmaceutical Companies, 2021 - 2031F |
6.4 Greece Oncology Companion Diagnostics Market, By Sample Type |
6.4.1 Overview and Analysis |
6.4.2 Greece Oncology Companion Diagnostics Market Revenues & Volume, By Blood, 2021 - 2031F |
6.4.3 Greece Oncology Companion Diagnostics Market Revenues & Volume, By Tissue, 2021 - 2031F |
6.4.4 Greece Oncology Companion Diagnostics Market Revenues & Volume, By Saliva, 2021 - 2031F |
6.4.5 Greece Oncology Companion Diagnostics Market Revenues & Volume, By Urine, 2021 - 2031F |
7 Greece Oncology Companion Diagnostics Market Import-Export Trade Statistics |
7.1 Greece Oncology Companion Diagnostics Market Export to Major Countries |
7.2 Greece Oncology Companion Diagnostics Market Imports from Major Countries |
8 Greece Oncology Companion Diagnostics Market Key Performance Indicators |
8.1 Adoption rate of companion diagnostics in oncology practices |
8.2 Number of new partnerships between diagnostic companies and pharmaceutical firms |
8.3 Rate of development and approval of new companion diagnostic tests |
8.4 Percentage of oncologists incorporating companion diagnostics in treatment decision-making |
8.5 Patient outcomes improvement rate due to personalized treatment using companion diagnostics. |
9 Greece Oncology Companion Diagnostics Market - Opportunity Assessment |
9.1 Greece Oncology Companion Diagnostics Market Opportunity Assessment, By Technology, 2021 & 2031F |
9.2 Greece Oncology Companion Diagnostics Market Opportunity Assessment, By Indication, 2021 & 2031F |
9.3 Greece Oncology Companion Diagnostics Market Opportunity Assessment, By End User, 2021 & 2031F |
9.4 Greece Oncology Companion Diagnostics Market Opportunity Assessment, By Sample Type, 2021 & 2031F |
10 Greece Oncology Companion Diagnostics Market - Competitive Landscape |
10.1 Greece Oncology Companion Diagnostics Market Revenue Share, By Companies, 2024 |
10.2 Greece Oncology Companion Diagnostics Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here